Cargando…

Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation

BACKGROUND: This study was done to investigate the long-term event free and overall survival of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), compared to maintenance chemotherapy (MT). Patterns of recurrences and late sequelae of both arms were analysed. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berthold, Frank, Ernst, Angela, Hero, Barbara, Klingebiel, Thomas, Kremens, Bernhard, Schilling, Freimut H., Simon, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068129/ https://www.ncbi.nlm.nih.gov/pubmed/29991700 http://dx.doi.org/10.1038/s41416-018-0169-8

Ejemplares similares

Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation
por: Berthold, Frank, et al.
Publicado: (2019)

Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma—Experiences From the GPOH-MET Registry
por: Kuhlen, Michaela, et al.
Publicado: (2022)

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
por: Simon, Thorsten, et al.
Publicado: (2011)

Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004
por: Jazmati, Danny, et al.
Publicado: (2020)

Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial
por: Berthold, Frank, et al.
Publicado: (2021)

64. wissenschaftliche Jahrestagung der GPOH
Publicado: (2004)

Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment
por: Luksch, R, et al.
Publicado: (2005)

Incorporation of high-dose (131)I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study
por: Lee, Ji Won, et al.
Publicado: (2017)

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification
por: Berthold, Frank, et al.
Publicado: (2021)

Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
por: Zhang, Dongdong, et al.
Publicado: (2021)

Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation
por: Vargas, Alberto Olaya, et al.
Publicado: (2013)

Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation
por: Kletzel, Morris
Publicado: (2013)

Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.
por: Pession, A., et al.
Publicado: (1998)

High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix)
por: Schorb, Elisabeth, et al.
Publicado: (2016)

Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma
por: Bae, Soo Jin, et al.
Publicado: (2012)

Double high-dose chemotherapy with autologous stem cell transplantation in patients with high-risk neuroblastoma: a pilot study in a single center.
por: Sung, Ki Woong, et al.
Publicado: (2002)

Gonadal Failure Is Common in Long-Term Survivors of Childhood High-Risk Neuroblastoma Treated With High-Dose Chemotherapy and Autologous Stem Cell Rescue
por: Utriainen, Pauliina, et al.
Publicado: (2019)

Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news?
por: Handgretinger, R, et al.
Publicado: (2003)

Induction Chemotherapy Followed by Chemoradiotherapy With or Without Consolidation Chemotherapy Versus Chemoradiotherapy Followed by Consolidation Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Xiang, Mingyue, et al.
Publicado: (2022)

Upfront consolidation treatment with (131)I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma
por: Feng, Jianhua, et al.
Publicado: (2020)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
por: Flaadt, Tim, et al.
Publicado: (2023)

High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients with High-risk Stage 3 Neuroblastoma: 10-Year Experience at a Single Center
por: Suh, Jung Min, et al.
Publicado: (2009)

Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantation.
por: Combaret, V., et al.
Publicado: (1989)

A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma: Children’s Oncology Group study ANBL00P1
por: Seif, Alix E., et al.
Publicado: (2013)

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-G(D2) immunotherapy and isotretinoin
por: Kushner, Brian H., et al.
Publicado: (2015)

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
por: Mora, Jaume, et al.
Publicado: (2020)

Abstracts der 96. Wissenschaftlichen Tagung der Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)
Publicado: (2022)

Autologous or allogeneic hematopoietic stem cells transplantation combined with high-dose chemotherapy for refractory neuroblastoma: A protocol for systematic review and meta-analysis
por: Zhao, Zhang-Shuai, et al.
Publicado: (2021)

Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months
por: Fischer, Janina, et al.
Publicado: (2017)

A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis
por: Kreitz, Kiana, et al.
Publicado: (2019)

Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
por: Tanos, Rachel, et al.
Publicado: (2016)

Association of PARP1 polymorphisms with response to chemotherapy in patients with high‐risk neuroblastoma
por: Avitabile, Marianna, et al.
Publicado: (2020)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
por: Cupit-Link, Margaret, et al.
Publicado: (2023)

Comparison of post-remission strategies in acute myeloid leukemia: Autologous hematopoietic stem cell transplantation versus consolidation chemotherapy
por: Yegin, Zeynep Arzu, et al.
Publicado: (2020)

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.
por: Philip, T., et al.
Publicado: (1986)

Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
por: Nucci, Marcio, et al.
Publicado: (2014)

A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma
por: Herd, Fiona, et al.
Publicado: (2019)

Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
por: Voglino, Valerio, et al.
Publicado: (2021)

Induction Fluorouracil-Based Chemotherapy and PET-Adapted Consolidation Chemoradiation with Esophagectomy for High-Risk Gastroesophageal Adenocarcinoma
por: Sinnamon, Andrew J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fb2rfqgeu6df94t32qn1odlhdv